67 results about "Dabigatran ethyl ester" patented technology

The invention relates to the technical field of medicament preparations, and discloses dabigatran etexilate self-emulsifying dispersible tablets and a preparation method thereof. The preparation method comprises the following steps: combining a certain proportion of dabigatran etexilate, an emulsifier and an assistant emulsifier into a dabigatran etexilate self-emulsifying solution; adsorbing by using a solid adsorbent to further obtain a solid self-emulsifying composition; and preparing the dabigatran etexilate self-emulsifying dispersible tablets by adopting a powder direct tabletting method. The dabigatran etexilate self-emulsifying solution and the self-emulsifying dispersible tablets prepared by the method disclosed by the invention can be self-emulsified in vivo after being orally taken to form a micro emulsion of which the particle size is about 200nm, so that the in vitro dissolution rate and in vivo intestinal absorption of dabigatran etexilate are significantly improved, and the in vivo bioavailability is improved.

The present invention provides a dabigatran tablet, including a dabigatran layer, an organic acid layer compounded on the surface of the dabigatran layer. The organic acid layer includes organic acid and a sustained-release material; the organic acid is citric acid or tartaric acid; the sustained-release material is one or more of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose and hydroxyethyl cellulose; the dabigatran layer includes dabigatran and a pharmaceutically acceptable salt thereof; the content of the organic acid is 20wt%-50wt%; and the content of the slow release material is 5wt%-20wt%. The organic acid in the dabigatran tablet can release at a constant speed or slowly, thereby reducing the stimulation and injury of gastrointestinal drugs, but does not affect the bioavailability of the drug. At the same time, the preparation method is more simple and easy to operate, reduces the production cost, and is easy to realize industrialization.

The invention relates to a dabigatran etexilate medicine composition and a preparation method thereof. The dabigatran etexilate medicine composition consists of a pill I and a pill II, wherein the pill I contains an active ingredient, a blank pill core material, an adhesive, an anti-sticking agent and/or an isolation material, wherein the active ingredient is dabigatran etexilate or a pharmaceutically acceptable salt, hydrate or solvate thereof; and the pill II contains a medicinal organic acid, a pill core material, an adhesive, an anti-sticking agent and/or an isolation material. The discovery shows that the active ingredient and the organic acid are respectively contained in the two different pills, so that the requirement of dissolving out the active ingredient is satisfied, and the active ingredient is more uniformly dissolved out; and in addition, an isolation effect between the active ingredient and the organic acid is enhanced, so that the stability of the dabigatran etexilate medicine composition is improved.

The invention discloses a preparation method for a dabigatran etexilate intermediate and an intermediate compound. The preparation method of the dabigatran etexilate intermediate 4 comprises the following step: in a protic organic solvent, reacting a compound 3 with a C1-C3 alkanol solution of methylamine. In the formula of the compound 3, X is chlorine, bromine or iodine. The invention also discloses the intermediate compound 3 and a preparation method of the intermediate compound 3. The preparation method for the dabigatran etexilate intermediate is simple and easy to operate, the yield is high, the product is easy to purity, and the preparation method is suitable for industrial production. The formula of the preparation method for the dabigatran etexilate intermediate is shown in the specification.

The invention discloses a production process of pradaxa mesylate. The production process comprises the following steps: (1) preparing an intermediate PR-I; (2) preparing an intermediate PR-II; (3) preparing pradaxa PR-III; (4) refining the pradaxa PR-III; and (5) preparing pradaxa mesylate. The production process is mild in reaction condition, simple in reaction route, convenient in operation, high in selectivity, and capable of shortening the production period; and the obtained pradaxa intermediate is low in water content, the prepared pradaxa mesylate is high in yield and purity, and the maximum impurity is low in impurity content; and the production process is less in emission of three wastes, environmentally friendly, free from requiring the columnar chromatography purification, suitable for the industrialized production, capable of avoiding the requirement of palladium-on-carbon high-pressure hydrogenation on equipment and capable of reducing the risk.

The invention provides a method for synthesizing a dabigatran etexilate intermediate, comprising: esterifying 3-nitro-4-methylaminobenzoic acid as a starting material with methanol to generate 3-nitro-4-methyl-(methylamino)benzoate, and carrying out catalytic hydrogenation reduction to obtain 3-amino-4-methyl-(methylamino)benzoate; carrying out closed-ring reaction to generate 1-methyl-2-chloromethylbenzimidazole-5-methyl formate; subjecting 1-methyl-2-chloromethylbenzimidazole-5-methyl formate to substitution reaction with 4-cyanoaniline to generate 1-methyl-2-(4-cyanophenylamino)methylbenzimidazole-5-methyl formate, and hydrolyzing to obtain 1-methyl-2-(4-cyanophenylamino)methylbenzimidazole-5-formic acid; amidating to generate a target product.The target product is synthesized through a converging synthetic process, reactive operations are simple, and the method is easy for industrial production.

The invention discloses a preparation method of novel N-substituted phenyl glycine (dabigatran ester intermediate). The preparation method of the novel N-substituted phenyl glycine comprises the following processes: carrying out condensation on glyoxylic acid and cheap and available substituted phenylamine (1) which is taken as a starting raw material to obtain imide; meanwhile, carrying out hydrogenation reduction to obtain N-(substituted phenyl) glycine. The preparation method of the novel N-substituted phenyl glycine has the advantages that the synthetic route is not reported before, raw materials are cheap and easily available; unit operation is easy, and equipment requirement is low, so that the preparation method of the novel N-substituted phenyl glycine is applicable to industrial production.

The present invention relates to a dabigatran etexilate pharmaceutical composition for injection, a preparation method and uses thereof, wherein the dabigatran etexilate pharmaceutical composition comprises: (1) an active substance dabigatran etexilate represented by a formula I-2, (2) a pharmaceutically acceptable solvent, and optionally (3) other pharmaceutically acceptable excipients. Accordingto the present invention, the test results show that various indexes of the dabigatran etexilate pharmaceutical composition meet the relevant drug regulations, and the safety, the resolubility and the long-term stability are good; the pharmacokinetic test results show that the dabigatran etexilate pharmaceutical composition can maintain the proper blood drug level and the proper treatment duration time in the body after administration, and the pH value is neutral so as to greatly reduce the stimulating effect on gastrointestinal tract; and the preparation method has characteristics of simplepreparation process, convenience, feasibility, good repeatability and low production cost, and is suitable for industrial mass production.

The invention provides an oral drug composition of dabigatran etexilate and a preparation method thereof, belongs to the field of pharmaceutic preparation, aims at providing oral preparation of the dabigatran etexilate which has the advantages of simple technology, easy implementation, lower cost, better active material dissolution and easy absorption and a preparation method for the oral preparation. The oral drug composition comprises (a) medicated particles composed of active material ingredients, adhesive, disintegrating agent and flow aid, wherein the active material ingredients are dabigatran etexilate or acceptable salt in pharmacy; (b) isolated organic acid crystals, wherein an isolating layer is made from an empty capsule I or an isolating material of acceptable cellulose-based auxiliary materials in pharmacy; a preferred isolating layer is made from the empty capsule I; and the medicated particles and the isolated organic acid crystals are evenly mixed in proportion and filled into an empty capsule II.

The invention relates to a preparation method of a benzimidazole derivative shown as a general formula I, wherein R1, R2 and R3 are defined as in the specification. The invention relates to a Dabigatran derivative shown as the general formula I and non-toxic pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing these compounds as active components, and application of the compounds and the pharmaceutical composition as thrombin inhibitors.

The invention discloses a preparation method of a dabigatran etexilate intermediate. The preparation method of the dabigatran etexilate intermediate 2 comprises that in an aprotic organic solvent, a compound 1 and a C1-C3 alkyl alcohol solution of methylamine undergo a reaction to produce the dabigatran etexilate intermediate, wherein X represents chlorine, bromine or iodine. The preparation method of the dabigatran etexilate intermediate has simple processes, can be operated easily, has a high reaction rate and a high yield, can be purified easily and can produce the product having high purity.

The invention relates to a method for synthesizing and preparing pradaxa formamidine intermediates. A concrete compound refers to 3-(2-(4-guanyl-phenylamino)methyl)-1-methyl-N-(pyridine-2-yl)-1H-benzo[d]imidazole-5-acylamino) alanine ethyl ester hydrochloride. The compound has the main purpose of preparing anticoagulants of methylsulfonic acid pradaxa formamidine. The method has the advantages that a solvent reducing method is adopted; the consumption of HCl/NH3 gas is reduced; in addition, the HCl solution is subjected to pressure reduction distillation under the relative low temperature condition; the distillation time is shortened; the requirements on the pressure resistance performance and the anti-corrosion performance of equipment are lowered; the impurity content is reduced. The invention also adopts a novel purification method; the solvent loss is reduced; the product purity is improved; the product cost is reduced.

An embodiment of the invention discloses a preparing method of dabigatran etexilate mesylate crystal form I. The method includes the steps of adding dabigatran etexilate into acetone solution before heating for solution, and adding methylsulfonic acid to generate dabigatran etexilate mesylate; stirring the dabigatran etexilate mesylate in ester solvent or ether solvent under heating so that the dabigatran etexilate mesylate with low crystal form I (containing little crystal form II or part of semihydrate) is converted into the dabigatran etexilate mesylate with high content of the crystal form I. The dabigatran etexilate mesylate crystal form I prepared by the method is high in purity, lower in water content and more stable in quality.

The invention discloses a medicinal combination containing pradaxa or salt and hydrate thereof. The medicinal combination comprises an active substance pellet core material containing an active ingredient pradaxa or pharmaceutically acceptable salt or hydrate thereof and filler and/or adhesive, an organic acid pellet core material containing organic acid and filler and/or adhesive, and an isolation layer which is arranged outside the active substance pellet core material and the organic acid pellet core material as shown in a figure I. By means of screening, the pradaxa active substance and organic acid are respectively prepared into pellet cores, and the pellet cores are respectively coated with the isolation layer, and the two pellets are prepared in a proportion to form the pradaxa oral medicine composition. The process is stable and controllable, and the preparation has good solubility and dissolution rate.

The invention relates to a pharmaceutical composition for oral administration, a preparation method and an application of the pharmaceutical composition as well as a modifying method of acid pharmaceutical adjuvants, wherein the pharmaceutical composition consists of a) the pharmaceutically acceptable surface-modified acid pharmaceutical adjuvants, and b) dabigatran etexilate, or pharmaceutically acceptable salt or a hydrate; and the modifying method comprises the following steps: preparing a pharmaceutically acceptable modifying alkaline substance water solution, and adding the water solution to powder particles of the acid pharmaceutical adjuvants, so that a neutral salt layer is each formed on the surface of the powder particles of the acid pharmaceutical adjuvants, so that hydrotropy can be performed by virtue of the acid adjuvants in a preparation prescription of the dabigatran etexilate, and meanwhile, the dabigatran etexilate can be prevented from being broken up by the acid adjuvants. The technology is also applicable to surface modification of alkaline pharmaceutical adjuvants, so that a neutral salt layer is each formed on the surfaces of the alkaline pharmaceutical adjuvants; therefore, the alkaline pharmaceutical adjuvants are prevented from being broken up by pharmaceutical active ingredients.

The invention relates to a preparation method of a benzimidazole derivative of a general formula I, wherein R1, R2 and R3 are defined in the specification. The invention relates to a Dabigatran derivative of the general formula I and non-toxic pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing these compounds as active components, and application of the compounds and the pharmaceutical composition as thrombin inhibitors.

The invention relates to the technical field of organic synthesis, in particular to a method for preparing dabigatran amidated impurities. The method includes subjecting a raw material, 4-aminobenzamidine-carbamic acid N-hexylester, to hydrolysis reaction to obtain a hydrolysate, and subjecting the hydrolysate and 3-[(3-amino-4-methyl amino benzoyl) pyridine-2-amino] ethyl propionate to condensation reaction under the action of a catalyst to obtain the dabigatran amidated impurities. The method has the advantages that final products, namely the dabigatran amidated impurities, can be obtained by the two-step method, the method is simple and easy to operate, high-purity composites can be obtained without chromatographic separation, and high-purity impurity comparison products can be provided for quality control of dabigatran drugs.

The invention discloses two methods of preparing a dabigatran etexilate intermediate 3-[N-(2-pyridyl)-3-amino-4-methylamino benzamido]-ethyl propionate (I).